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ABSTRACT
Therapeutic Drug Monitoring (TDM) is a key concept in precision
medicine. The goal of TDM is to avoid therapeutic failure or toxic
eects of a drug due to insucient or excessive circulating concen-
tration exposure related to between-patient variability in the drug’s
disposition. We present TUCUXI – an intelligent system for TDM.
By making use of embedded mathematical models, the software
allows to compute maximum likelihood individual predictions of
drug concentrations from population pharmacokinetic data, based
on patient’s parameters and previously observed concentrations.
TUCUXI was developed to be used in medical practice, to assist
clinicians in taking dosage adjustment decisions for optimizing
drug concentration levels. This software is currently being tested
in a University Hospital. In this paper we focus on the process of
software integration in clinical workow. The modular architec-
ture of the software allows us to plug in a module enabling data
aggregation for research purposes. This is an important feature in
order to develop new mathematical models for drugs, and thus to
improve TDM. Finally we discuss ethical issues related to the use
of an automated decision support system in clinical practice, in
particular if it allows data aggregation for research purposes.
CCS CONCEPTS
• Information systems → Expert systems; • Applied comput-
ing → Health care information systems;
KEYWORDS
Automated TDM, personalized medicine, clinical information sys-
tem, data integration
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1 INTRODUCTION
Millions of people have to take a variety of medications every day.
Unfortunately, treatments are not always eective in all patients.
One reason for this is that dierent patients absorb, metabolize and
eliminate drugs dierently. Patients’ response to a drug may depend
on genetic makeup, age, body size, presence of kidney or liver
diseases, drug-drug interactions, time of the day, etc. Therefore, the
drug dose may be either insucient and the patient will not benet
from the treatment, or excessive, which may cause serious toxicity.
This is especially relevant to critical medications such as anti-cancer
or anti-HIV drugs, which have both a narrow therapeutic range and
a poorly predictable relationship between the dosage prescribed
and the drug concentration exposure obtained in patients’ blood.
For example, for the antiretroviral drug Rilpivirine used in the
treatment of HIV patients, the target minimum concentration is
44ng/ml. However, it has been shown that on average four pa-
tients out of ten have Rilpivirine concentrations below the target.
Therefore, a risk of insucient ecacy exists in 40% of the patients
treated with the standard dosage [2].
The problem of inappropriate dosing has been reported in medi-
cal literature [2, 4] and the TDM approach has been proposed as a
corrective measure. TDM involves the measurement of drug concen-
trations in biological samples and the improvement of drug dosage
to improve drug ecacy and reduce related toxicities [11, 16, 18].
TDM has evolved to become an important tool used for adminis-
tration of antiarrhythmic and psychiatric drugs, anticonvulsants,
anticancer agents, immunosuppressants, and antifungals [15].
Pharmacokinetic and pharmacodynamic (PKPD) models for nu-
merous drugs are being developed by clinical pharmacologists to
describe how the body handles a drug in terms of absorption, distri-
bution, metabolism, and elimination (PK models). PD models then
describe how a drug aects the body by linking the drug concen-
tration prole to one or several ecacy metrics. PKPD models are
ideally suited to summarize the background knowledge necessary
to adjust the drug dosage in a given patient [15].
However, in everyday clinical practice, it is fairly dicult for a
clinician to make use of these PKPD models available only in scien-
tic literature, and to apply them in every specic patient’s case. A
consultation with a pharmacologist may not be arranged shortly
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and will require the pharmacologist to collect a sucient amount of
information on the patient’s clinical history before issuing a valid
recommendation for dosage adjustment. Still an appropriate correc-
tion of drug dosage may be of critical importance if concentration
exposure is signicantly away from the targets ensuring optimal
treatment ecacy and tolerability.
In order to address these issues, an automation of TDM is pro-
posed. Existing software for TDM computer assistance has been
surveyed by Fuchs et al. [10]. However, an intelligent system in-
tegrated in everyday clinical practice, allowing precise and rapid
evaluation and adjustment of drug dosages, and simultaneously
making the data available for the development of new PKPD models,
is still missing.
Our development had to address the following challenges:
• Interdisciplinary collaboration. Mathematical models devel-
oped by researchers in clinical pharmacology need to be
embedded in a user-friendly software suitable to be used
by medical doctors/pharmacologists.
• Ergonomy. The software has to eciently help medical
doctors and pharmacologists by being well suited to the
actual processing ow of TDM requests faced daily.
• Medical device certication.According to current regulation,
such a system is a medical device and as such needs to be
certied in order to ensure proper functionalities without
risks of harming patients.
• Interoperability. The software requires seamless insertion
into the existing network of electronic medical records,
laboratory information system and other medical applica-
tion, thus raising issues related to dierent interfaces, data
formats, comprehensive clinical data ow etc.
• Data aggregation for research. The collection of population
data from daily use of the software would be ideally suited
to improve existing models and to develop new PKPD mod-
els for drugs candidate to TDM. However, patients’ data
are sensitive, studies may have very dierent scopes, and
data aggregation is time consuming.
• Ethical issues. Automated processing of TDM raises a ques-
tion of medical liability regarding highly sensitive aspects
of patients’ management such as dosage decisions.
In this paper we present TUCUXI– a software that was devel-
oped and integrated into the clinical data ow in order to provide
automated dosage evaluation and adjustment decisions to assist
pharmacologists or medical doctors. The modular architecture of
the software allows to plug in dedicated modules for data aggrega-
tion for research purposes. These data are to be used by researchers
to improve or develop PKPD models for TDM.
The advantages of our solution are the following ones. First, it
provides personalized dosage adjustment advice based on reference
population PKPD data, patient’s individual characteristics and con-
centrations previously observed, if available. Second, it optimizes
TDM procedures and thus enables to process large numbers of re-
quests; therefore it contributes to extend the use of TDM and the
number of patients that may benet from TDM services. Third, it
provides an interface with other clinical applications, and could
be easily integrated into primary care and also used for medical re-
search. Finally, our solution also allows to decrease the risk of human
mistakes.
The rest of the paper is organized as follows. In Section 2 we
present current non-automatized processes of routine TDM in hos-
pital settings and its diculties. We describe the developed software
in details in Section 3 along with its integration into the clinical data
ow in Section 4. In Section 5 we discuss how the software enables
data aggregation for research purposes. In Section 6 we discuss
ethical issues related to the use of an automated software in clinical
practice, to its validation, and to the aggregation of sensitive pa-
tients’ medical data to improve TDM and therapeutic outcomes. We
compare our software with currently existing solutions in Section
7 and we eventually express our conclusions about the evolution of
TDM in Section 8.
2 TDM IN CLINICAL PRACTICE
Non-automated therapeutic drug monitoring, as currently prac-
ticed in most places, is a comprehensive and rather slow process.
We studied the related procedures in actual medical practice at
a University Hospital, where clinical pharmacologists work on a
daily basis to provide dosage adjustment advice to medical doctors
working either in the same hospital or elsewhere in the country.
The sequence diagram shown on Figure 1 (a) describes non –
automated TDM1. The process begins when a patient starts receiv-
ing treatment with a drug considered to require TDM. In this case,
after a couple of intakes, a blood sample is drawn to monitor the
plasma concentration of the drug. The medical doctor in charge of
the patient prescribes the test and requests to send the patient’s
sample together with appropriate data to the laboratory, where con-
centration measurements are performed (steps 1 – 5 of the diagram
on Figure 1a). Then, next step (6): the data are transfered into a
laboratory information system, where they are stored and will be
accessed by the pharmacologist in charge of clinical interpretation
of the measurement result, after its validation.
When the pharmacologist receives a request to interpret a drug
concentration value, as already mentioned above, he needs to collect
a certain amount of medical information regarding the patient’s
case. To do so, he may need to access multiple databases that store
information about the the patient’s clinical history, medication
records, laboratory results, etc. (steps 7 – 12). The pharmacologist
will also need to refer to PKPD models for the drug existing in the
scientic literature (as step 15 indicates it). If any information about
the patient is missing, a phone contact with the medical doctor that
initiated the TDM request is also needed (steps 13 – 14).
When all the information is collected, the pharmacologist elab-
orates an interpretation of the laboratory result (16). At present,
this is essentially made on an empirical basis. Some rare pharma-
cologists rely on models built up with custom tools (such as Excel),
which can accommodate patient’s medical characteristics and just
one or sometimes two concentration measurements. Only a small
minority of centers regularly use one of the commercially available
dedicated software tools, considered of insucient ergonomy for
1In order to simplify graphical representation of the processes on both sequence
diagrams on the Figure 1 we do not show existing interfaces and proxies that can be
modeled as boundary object and control objects and placed between actors and entity
objects on the UML diagram.
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Figure 1: TDM in clinical practice: non-automatized process (a), TUCUXI (TDM software) integrated in clinical practice (b).
implementation in everyday routine [10]. The results and updates
are sent to the hospital electronic medical record, which the physi-
cian that initiated the TDM request can now access (as presented
by steps 16 – 21).
While working on each particular patient case, a pharmacologist
has to access multiple sources of data, perform various estimations
or calculations, switch contexts. Not only are current procedures
slow and poorly ecient, but they also may increase the risk of hu-
man mistakes, which could signicantly aect patient’s condition.
When clinical pharmacologists are not available in the hospital,
most laboratory results are sent without interpretation to the physi-
cians that have requested TDM. Most physicians tend to translate
TDM results into dosage adjustments according to an empirical
trial-and-error strategy – which should not be entirely denigrated
though, as it often ts clinical needs to a sucient extent. In ex-
ceptional cases another institution will be contacted (such as the
Hospital we are collaborating with). However, this may cause even
longer delays due to the need to transfer the data, to clarify missing
details about patient’s history (due to the lack of interoperability be-
tween dierent hospitals, e.g., data stored in an hospital can only be
accessed internally due to their sensitive nature), and to elaborate
the pharmacological interpretation requested.
In order to optimize highlighted steps 7 – 20 of the diagram on
Figure 1a, and to tackle the diculties listed above, we propose to
integrate a TDM software in the clinical data ow. The software
provides an interface that guides the user through the TDM process,
provides required information about the patient and employs PKPD
models built up using population data and integrated into the soft-
ware. This allows not only to interpret the current concentration
value but also to predict future drug exposure, and to suggest a
personalized dosage adjustment for the patient. Figure 1b presents
the sequence diagram of the data ow using TDM software TU-
CUXI integrated in clinical practice. One can notice that the ow is
simplied (steps 7 – 13), and also includes populating a research
database for building up new PKPD models (steps 14 – 15).
3 TUCUXI AND EMBEDDED
MATHEMATICAL MODELS
A software helping the clinicians in their daily practice can be
conceived as a standalone software embedding a graphical user
interface (GUI) or as a service hidden behind a client. We present
here the GUI version, and we will discuss the service possibilities
in Section 6.
3.1 Software Description
TUCUXI core capabilities can be segmented into three main parts:
(1) Computation of concentration percentiles and comparison
with therapeutic targets, based on the patient’s dosage
regimen and clinical characteristics, as well as on reference
PKPD data ;
(2) Computation of concentration predictions based on the
same data confronted with the patient’s observations ;
(3) Suggestion of dosage adjustments in order to drive the
resulting concentration exposure into the therapeutic tar-
gets.
The general architecture is made of layers. The rst layer is pure
mathematics, implemented in a very optimized way. It ensures the
three core capabilities listed above. The second layer (processing
layer) is responsible for translating Domain Model Objects into
mathematical objects and then calling the math functions. On top
of this second layer the GUI exploits the processing layer and an
interconnection module to create the nal software.
The following subsection gives some insight corresponding to
the three main mathematical software parts.
3.2 Mathematical Engine
3.2.1 Concentration calculation. Prediction of drug concentra-
tion can be done through model-free systems (e.g., Support Vector
Machine [23]) based on population data, or through model-based
systems. The model-free approach may be well suited for predicting
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concentration at a specic time (typically time of measure), but
often suers from limits of applicability (depending on the method,
concentrations below zero could be calculated). The model-based
approach is more suited for continuous curves, and is used by a
majority of pharmacologists (also because it allows to explain the
calculation in a physiological way).
The concept is to model the human body in terms of compart-
ments exchanging substances. The drug concentration is typically
measured in blood, so a central compartment corresponds to the
entire blood veins and arteries. Models can have more than one
compartment, and if such, the muscles are a typical second compart-
ment. Taking a drug is seen as an input to a specic compartment,
and the drug elimination corresponds to a ow leaving one of the
compartments. Figure 2 represents a 2-compartment model for
bolus injection.
Figure 2: 2-compartment model
Constants ke , k12, k21 are used to describe the ow between the
compartments. For example, here the dierential equations are, for
concentrationC1 andC2, respectively in compartmentsV 1 andV 2:
dC1
dt
= k21C2 − k12C1 − keC1,
dC2
dt
= k12C1 − k21C2.
It is to be noted that in this case, administrating a drug con-
sists in adding a certain amount at the time of administration in
compartment V 1.
The constants are directly derived from population studies, typi-
cally published by pharmacologists for a specic set of patients. The
equations presented above exploit so-called micro-constants that
are calculated from macro-constants (clearance, volume, ...). De-
pending on the complexity of the dierential equation, analytical
solutions are available and more ecient in terms of computa-
tion time. For linear elimination models up to 3 compartments,
such analytical solutions exist, but for other models (e.g. Michaelis-
Menten [17]) only dierential equations are available.
The macro-constants and the dosage history dene exactly the
prediction curve shape. The question is then about the way of
evaluating these constants.
From a population pharmacokinetics study, the authors usually
present parameters (macro-constants), their variability, consisting
in inter-individual variability, an intra-individual variability, and
the inuence of patient covariates onto the parameters.
Based on this data, TUCUXI can rst calculate predictions for
the so-called typical patient. For each study, the average parameter
values correspond to such a typical individual, and if no information
is available about a patient, this calculation gives a rst approxi-
mation of what could be the observed concentration based on the
medical drug intakes.
If patient’s covariates are known, the published models propose
to adapt the average parameters thanks to update functions. This
kind of adaptation is referred to as a priori calculations and re-
sults in a prediction reecting more precisely the concentrations
expected for a specic individual. Typical covariates are age, gen-
der, or weight, but TUCUXI can handle any kind and number of
covariates for a specic model.
Finally, the most accurate prediction is made when, in conjunc-
tion with covariates, the software “knows“ the results of real concen-
tration measurements done at specic times. The method currently
implemented is based on a maximum likelihood function mixed
with a Bayesian approach. It allows to take into account the popula-
tion statistics as well as the measures, by exploiting the intra- and
inter-individual variability. The resulting a posteriori prediction is
the one used for the dosage adjustment.
3.2.2 Percentiles calculation. While prediction is at the core of
TUCUXI , percentiles are essential in order to evaluate the normality
of a patient response with respect to the population. Percentiles are
calculated thanks to a Monte Carlo simulation exploiting the intra-
and inter-individual variability. A particular attention was put on
the implementation of this part of the software, as Monte Carlo
simulations can be very slow. An in-depth optimization allows to
calculate useful percentiles in around a second on a standard PC.
Typically these percentiles allow to evaluate the likelihood of a
specic concentration measurement and will help the pharmacolo-
gists to better interpret the supplied result.
3.2.3 Dosage adjustment. Finally, TUCUXI not only calculates
predictions and percentiles, but also can propose dosages adjust-
ments. The software can issue recommendations on the amount of
drug to be administrated, the interval between intakes, and on the
infusion time in case of infusion intake. So, up to three values can
be tted to match the best treatment for a specic person. The goal
is that concentration predictions actually match therapeutic targets.
These targets can be of various types: (1) residual concentration
(before the next intake), (2) peak concentration (typically 1 hour
after the intake), (3) mean concentration, and (4) area under the
curve (AUC). Fitness functions for each specic targets have been
designed and are used to nd the best combination of dose-interval-
infusion. A score is therefore given to each combination and can
be used to select the best candidates. It is to be noted that for each
medical drug, a selection of discrete values is available so as to re-
duce the search space and more importantly to keep the treatment
feasible. For instance, the authorized intervals are 8, 12, 24 and 36
hours and the doses correspond to the available drug formulations
(e.g. pills, tablets, capsules), or possibly simple fractions of them
(e.g. scored tablets).
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3.3 Interface for Clinicians
TDM as performed every day in specialized institutions is based on
custom tools and needs to be done rapidly in order not to cost too
much time (and money for the institution). There is a real need for
a software facilitating the clinicians’ decisions. Therefore TUCUXI
has been designed in close collaboration with pharmacologists. It
reects their thinking while performing TDM interpretation.
Figure 3 shows the GUI. The work ow is represented thanks
to the buttons allowing to navigate through the various screens
(or panels). Each button corresponds to a specic screen showing
information related to a particular part of the process.
It is important to dierentiate two use cases of the software:
(1) Standalone. A non-connected use where the user has to
enter all the data by himself.
(2) Connected. A connection to an institutional database al-
lows to retrieve a full set of data (cf. Section 4).
The two ows are run on the same GUI with the dierence being
that for the second use case the user mostly has to acknowledge
the correctness of data instead of lling himself the forms. It is
interesting to notice that the connected ow could be totally auto-
mated, except for the suggestions writing by the medical doctor.
This automation corresponds to a server version without human
interaction, as discussed later in Section 6.
The ow, corresponding to the current pharmacologists prac-
tice is decomposed into 9 panels, shown from left to right on the
GUI (cf. Figure 3). They are described in the following lines, with
some information about dierences between the standalone and
the connected ow.
(1) Patient information. This panel simply allows to check
and complete if necessary administrative data about the
patient. The most important part here is the birth date, as
most of the models use this information as a covariate.
(2) Medical drug selection. For a standalone use, the user
has to select the medical drug (the active substance), and
the model to be used. This model can be dependent on
the patient information (Caucasian or not, neonate, child
or adult, for instance). For the connected use, the active
substance is already dened, and only the model needs to
be selected. This model selection could be automated in
the future, based on patient data if available.
(3) Dosages. Past dosages are introduced within this panel.
For a connected use, these elds can be fed from the elec-
tronic medical record.
(4) Patient covariates. Patient covariates are sensitive infor-
mation. The models exploit them in order to more accu-
rately predict the expected drug concentration. In stan-
dalone mode, the covariates used by the selected models
are displayed and can be modied by the user, while in
connected mode, most of these variables are automatically
retrieved from the electronic medical record. The predic-
tion curve displayed on this panel corresponds to the a
priori prediction, with the corresponding percentiles.
(5) Drug concentration measurements. Observed concen-
trations are dened within this panel, or automatically
fetched. From this panel up to the end of the ow, the pre-
diction curve corresponds to the a posteriori prediction,
taking into account the covariates and the past measure-
ments.
(6) Targets. Before proposing an adjustment, the software
allows to validate or modify the target concentrations. In
most cases the default target values of the medical drug will
be used, but if the physician has more patient’s information
that could aect the desired targets he can modify them.
(7) Adjustment. Based on all data lled up to this point, TU-
CUXI can propose an automatic drug dosage adjustment.
Valid propositions are displayed in a list sorted by accuracy.
The user can then select the most appropriate, which will
be submitted as a recommendation and added to the list of
dosages.
(8) Validation. After the selection of the best adjustment, the
user can enter text that will be appended to the nal report.
Five dierent elds serve to guide the type of information
required: expectedness, suitability, prediction, remonitor-
ing and warning.
(9) Report generation. Finally, a report is automatically gen-
erated. It contains all data about the patient, a prediction
curve, the kinetic parameters, and the text entered by the
user. A PDF le can then be exported and potentially sent
to the medical records database.
As TUCUXI is a medical device, ensuring that data are correct is
highly important. In standalone mode, it is reasonable to make the
assumption that the user is responsible of lling the data correctly.
However, in connected mode, almost all data are automatically
retrieved from a database. The user needs to acknowledge he went
through all the panels in order to validate the interpretation. The
validation status is shown on each ow button (see yellow circles
in gure 3). These buttons can have three states: invalid, valid
and validated. Data retrieved from the database is marked as valid,
except if some elds cannot be correctly casted, and the user has to
click on the circle to validate it. In gure 3 the validation and report
panels can not be accessed because the user did not yet validate
the rst 7 panels. The development team took this decision based
on the risk analysis of the software, in order to ensure the user is
aware of the data used to predict concentrations and to propose
adjustments.
4 TUCUXI INTEGRATION IN CLINICAL
PRACTICE
Usually, the pharmacologist receives a list of pending requests for
TDM interpretation. He selects a request from the list to analyze
the concentration of the drug and evaluate the dosage adjustment
called for. For each request he needs to query additional specic
information about the corresponding patient. In this section we
describe the process of integration of the TDM software presented
in the previous section in clinical data ow. First, we show how the
interoperability was achieved. Second, we present data structure
and messages designed to exchange the data.
4.1 Interfaces for data exchange
In order to integrate the TDM software described in Section 3 into
the clinical data ow presented above we had to dene how to
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Figure 3: TUCUXI graphical user interface
exchange healthcare data between heterogeneous systems that sup-
port dierent data formats. Medical data are stored and exchanged
between clinical databases in HL7 format. However, the software
operates the data in XML format and produces the reports and
graphs in PDF and PNG format. To solve this interoperability issue
Mirth Connect 2 – an open source healthcare integration engine –
has been used.
Clinical	  DMBS	  
DMBS	  
channel	  
REST	  (POST)	  
over	  HTTP(S)	  
MLLP	  Tucuxi	  
channel	  
query/reply_list	  
query/reply_request	  
noBﬁcaBon	  
ack	  
Tucuxi	  
Figure 4: Communication between TUCUXI and the data-
base of the medical institution
Figure 4 shows the actors involved in the process of data ex-
change and the formats of the data they use. We use a client-server
architecture with a proxy to model communication between TU-
CUXI and clinical database management system (DMBS). We cre-
ated two external channels for communications: one for TUCUXI -
Mirth and one for DMBS-Mirth; and four channels were deployed
2https://www.mirth.com
on Mirth for the data transformations. To connect TUCUXI to an-
other system there is no need to modify the software, only one
Mirth channel may need to be adapted.
Communication between TDM software and proxy is done us-
ing a REST API. Sending a query or an update is initiated via an
HTTP(S) request that encapsulates the corresponding message in
XML format (cf. Figure 5). The client TUCUXI can send 2 types
of query requests, an acknowledgment message (when a response
is received) and a notication to update the DMBS. For each type
of these messages the separate channel is deployed on the proxy
and a message is ltered to the corresponding channel based on
the message type. For all the messages sent by TUCUXI except the
acknowledgment (there is no response for the ACK), the response
will go through the same channel and will be transformed from
HL7 format to XML. Transformations are dened separately using
javaScript for each type of message.
Communication between Mirth and clinical DMBS is dened
according to the Minimal Lower Layer Protocol (MLLP) – a standard
for transmitting HL7 messages via TCP/IP.
We have implemented the data ow as shown on Figure 5. The
sequence diagram that describes the data ow consists of the fol-
lowing steps:
(1) Obtaining the list of pending requests ;
(2) Obtaining the detailed data about specic request ;
(3) Individual dosage evaluation, adjustment proposition ;
(4) Sending results to the medical database.
At the source/destination of these channels we deployed a trans-
former using javaScript that perform the mapping and construct
messages of each type required by the clinical ow. All the messages
are received on an external channel that redirects the messages
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Figure 5: Communication diagram for the clinical data ow
with TUCUXI
based on the lter dened with respect to the message header where
the type of the message is specied.
4.2 Data structure and messages
In this subsection we present the content of the messages we con-
structed for data exchange between TUCUXI and a clinical database.
Following the clinical ow of TDM we need to provide the user of
the software (doctor, or pharmacologist) with the list of pending
requests. A user can specify a time frame that will be an inclusion
criteria for the requests based on their arrival date. According to
standardized procedures of routine non-automated TDM in the hos-
pital a code “CPCL“ with the value “4CPCL“ (“0CPCL“) is used to tag
whether request has (not) been already processed by a pharmacolo-
gist. Therefore in order to ask for the list of requests, a QUERY LIST
message contains the time interval corresponding to the sampling
arrival date/time and CPCL value: “0CPCL“.
A REPLY LIST message is a list of pending requests and it con-
tains, for each request, the following information:
• request Id – a unique identier of the request within the
clinical system ;
• CPCL code value ;
• information about the patient such as covariates (gender
and age), as well as address and the patient identier in
the clinical system ;
• practitioner data: information about the doctor that pre-
scribed the test, and the medical institution, if the sample
is sent by another hospital ;
• sample data: identier of the sample (identier of the tube
form the laboratory), the date/time of the sampling and
sample arrival date/time in the laboratory ;
• information about the drug: code used in the system, active
principle, brand name, Anatomical Therapeutic Chemical
(ATC)3 classication system code.
3www.whocc.no/atc_ddd_index/
This information allows the pharmacologist to ensure that the sam-
ples with the medications that require urgent analysis are validated
on time.
To obtain more information about the request selected for vali-
dation, the QUERY REQUEST message is sent to the clinical database
system. Multiple drugs can be measured in one sample and several
samples can correspond to the same patient. Therefore, a QUERY
REQUEST contains the patient unique identier, request id and drug
id. This combination uniquely identies a request for validation of
the drug.
REPLY REQUEST message in comparison to QUERY LIST contains
extended information such as the following:
• dosages: start of the treatment or the date of last change of
dosage, date/time of the last dose intake, current dosage,
frequency of intake, route of administration, comments
provided by the clinician ;
• sample results, containing observed concentration analyte
and corresponding value and unit ;
• additional patient’s covariates required for the drug model:
bodyweight, renalfailure (y/n), lastcreatinine, hemodialysis
(y/n), hemoltration (y/n), gestationalage (for newborns),
liverfailure (y/n), childpugh, heartfailure (y/n), lungfailure
(y/n)), together with the value, unit and the date/time date
of the covariate’ s acquisition ;
• Timestamped clinical data such as clinical diagnosis, the
adverse eects information (toxicity), indication that cor-
responds to the motivations to TDM, response.
While the REPLY LIST message contains the information that
can help the clinician to review and choose next request to be
validated, extended information from the REPLY REQUEST is used to
ll in (or pre-ll) the panels (1)-(6) of the software. When a request is
processed, and the report is generated, the NOTIFICATION message
is sent to the clinical database with the following information:
• expectedness: the interpretation of the normality of the
result by the analyst ;
• suitability of the treatment: the interpretation of the ap-
propriateness of drug exposure by the analyst ;
• prediction: the recommendation of dosage adjustment by
the analyst ;
• remonitoring: the recommendation for future monitoring
by the analyst ;
• a priori and a posteriori parameters of the mathematical
model ;
• some cautionary statement by the analyst and the times-
tamp of the interpretation ;
• image of the expected curve (in a binary format in base-64) ;
• report described in Section 3 generated automatically ;
• CPCL code with the value "4CPCL", corresponding to the
validated request.
If any information about the patient has to be modied (due
to a possible mistake originated from clinical database) it can be
updated using a NOTIFICATION message.
When TUCUXI receives a REPLY LIST or a REPLY REQUEST
message an ACK message is sent to the clinical database to acknowl-
edge reception of the messages from clinical DBMS. Reception of
NOTIFICATION is acknowledged by the clinical DMBS as well.
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While constructing the messages with the the information listed
above in HL74 v2.4 format, custom segments were introduced. Cus-
tom segments were used to express status of the request (validated
or awaiting validation), information about drug and dosages, some
clinical data, the report and the curve with the predicted concen-
tration, as well as a priori and a posteriori parameters of the math-
ematical model. For each query/reply pairs we dene so-called
Conformance Statement – the information that identies the query,
species what items can be queried and describes what the response
will look like.
5 FROM DROP OF BLOOD TO RESEARCH
DATABASE AND BACK
Research studies that use retrospective medical data have become
a major source of contributions to the biomedical science litera-
ture [12]. Therefore, data aggregation for the research purposes
is a essential step towards enhancing clinical literature, e.g., by
developing new PKPD models.
Figure 6: Connecting multiple instances of TDM software
Figure 6 shows the data ow in a healthcare system spanning
from a patient bedside to the healthcare data aggregated in the
cloud and used for the research purposes.
Characteristics of the data to be acquired for a research study
are determined by the requirements of the study. Therefore, mul-
tiple databases need to be constructed. For this we need a system
that will connect researchers and medical institutions and will al-
low them to collaborate with each other and will enable dynamic
data aggregation. We assume that the number of data sources par-
ticipating in the data aggregation should not be static as well as
description of the data to be aggregated (could be adjusted during
the process of data aggregation depending on the data availabil-
ity) [6]. Dynamicity of such system will allow one to accelerate a
notoriously time-consuming data collection process.
We developed a mutli-agent system for dynamic data aggregation
for the research purposes. An agent is modeled as an instance of
TUCUXI used by a doctor or in a hospital. It has been tested using
anonymized TDM data and presented in detail in [6].
In clinical practice unless the patient provided a consent for
sharing the data as they are, the data have to be anonymized. We
4http://www.hl7.org.
also developed a privacy-preserving algorithm for distributed data
aggregation for medical research [7] that can be used to ensure
anonymity of the patients. However, anonymization may aect
the utility of the data. To overcome this issue we are currently
evaluating an algorithm that will allow to improve the data utility
with the database growth while preserving patient’s privacy.
Expanding TDM to a larger patients population by making it
available at the Point-of-Care (POC) system will further advance
the outcome of drug therapies. Key for widespread dosage adjust-
ment is the availability of point-of-care devices able to measure
plasma drug concentration in a simple, automated, and cost – ef-
fective fashion. Cappi et al. introduce and test such POC device.
The authors present a portable, palm-sized transmission-localized
surface plasmon resonance (T-LSPR) setup, comprised of o-the-
shelf components and coupled with DNA-based aptamers specic
to the antibiotic tobramycin [5]. Mobile version of the software
e.g., running on the POC (cf. Figure 6) or on the tablet connected to
POC, can be used to alert a patient in case of toxicity of inecacy
of the treatment and provide a recommendation to ask for medical
assistance. Dosage adjustment can be made faster as there is no
need to send the blood sample to a laboratory and to wait for the
results to be transmitted back [5]. The results from POC could also
be sent to the patient’s cloud database, accessed by the clinician or
pharmacologist and analyzed using TDM software.
6 DISCUSSION
In this section we discuss the ethical issues related to the use of
automated software to manage patient’s healthcare data.
6.1 Ethical issues
6.1.1 Decision making in medical domain. A piece of software
like TUCUXI does not aim to replace physicians, but rather to pro-
vide assistance in TDM. Dosage individualization is suitable or even
required for many drugs, but it is dicult and time consuming, the
way it is done at present. Current tools such as Excel worksheets or
non-ergonomic softwares are not well suited to manage heteroge-
neous patients’ data in order to issue dosage adjustment decisions
on a large scale. Moreover, the time required for a consultation with
a clinical pharmacologist may delay important adjustments of the
treatment. We think it is possible that clinicians use our software
without consulting a specialist in pharmacology. For this we need to
ensure "safety" of the software, i.e. its ability to detect unusual cases
and to produce reports of no worse quality than those produced by
trained clinical pharmacologists.
Before using any PKPD model for a given drug, the model will
require approval by a trained pharmacologist after thorough testing.
A semi- or fully-automated procedure may contribute to ecient
validation of such drug models in the future. Certication of the
whole software along with its reference PKPD database is required.
Currently we are developing the necessary trials to make it a vali-
dated medical device according to applicable regulation.
6.1.2 Evaluation of TUCUXI as a TDM soware. A recent re-
view [19] describes four steps to implement pharmacometrics-
based decision support tools, consisting of validating scientic
components, dening technical options, considering regulatory
aspects, and achieving ecient commercialization. Examples of
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pharmacometrics-based decision tools that support monitoring of
patients and individualization of treatment strategies in neonates,
children and adults are presented. Concretely, the evaluation of a
medical software such as TUCUXI requires several tasks:
(1) Verication of the Correctness of implementation of
mathematicalmodels, for instance, using automated math-
ematical validation of the software against NONMEM – the
de facto standard for studies in pharmacokinetics [3].
(2) Validation of data exchange through a series of scripts
aiming to obtain the list of pending TDM requests, run
multiple times a day.
(3) While the rst two tasks are being run automatically every
day, thanks to scripting facilities, clinical validation re-
quires a real validation in clinical practice. An evaluation
protocol has been designed and is meant to be used after
the rst two tasks proved the correctness of the software.
6.1.3 Fully automated TDM. While the GUI version of TUCUXI
is currently being tested, a next server version is under development.
Its goal is to be able to propose an automated interpretation based
on all data sent to the server. Basically it is meant to work as the
GUI version, but automatically calculating predictions and dosage
adjustments. A report will be generated, with graphs and a list
of best dosage candidates for the specic patient. This server will
allow to be integrated into an electronic patient infrastructure, as a
service for analysis labs. Ethically speaking, a human should still
be responsible to check the report and to choose the best dosage.
6.2 Patient’s privacy
Having access to the population data is crucial for building new
mathematical models, or improving characteristics and parame-
ters of the existing ones. According to the current data protection
legislation in US5 and in Europe [9], as well as to the EU General
Data Protection Regulation (GDPR) that will replace the European
Data Protection Directive 95/46/EC starting from 25 May 20186,
collecting and sharing personal data require signed consent from
the patient to allow using his data for research purposes. Not all
patients are willing to provide consent due to the risk of their data
misuse [21, 22]. For example, if the healthcare data become publicly
available insurance companies may infer that a person has a chronic
disease susceptibility, and may refuse an application or reject the
renewal of their insurance policy. An employer may try to infer
healthcare information about potential employees and based on
the sensitive information (a serious health condition or a chronic
disease susceptibility) may discriminate the candidate [6]. As an
alternative to the consent collection, the data can be anonymized:
the patient’s data to be used for the research must not be linked to
the identity of a person to whom these data belong [8, 9].
How to ensure that the data that may belong to the same pa-
tient and were aggregated from dierent sources were properly
anonymized? In [7] the authors proposed a privacy-preserving
algorithm for independent release of medical data in distributed
environment. However, one should take into account that absolute
anonymization is only possible when no data are shared at all and,
5http://www.hhs.gov/hipaa/
6http://www.eugdpr.org/eugdpr.org.html
therefore, the privacy-utility trade-o needs to be found for every
specic case. How to automatically adapt this trade-o for dier-
ent databases? What is an acceptable risk of violation of patient’s
privacy? These questions still remain open.
7 RELATEDWORK
Fuchs at al in [10] present a review of twelve available clinical phar-
macokinetic computer tools. The authors also describe the history
and evolution of the software dedicated to monitoring and dosage
adjustment staring from the software developed by Laboratory of
Applied Pharmacokinetics at the University of Southern California
(Los Angeles, CA, USA), launched in 1973 [14], and evolved to the
BestDose7 to the available8 software packages such as MwPharm
[20] and TCIWorks [25] that turned out to be the best ranked TDM
programs according to the review [10].
MwPharm has the largest database of drugs with their pharma-
cokinetic properties and almost 300 population models embedded
in the software. However, similarly to BestDose it is also a stan-
dalone TDM software. This means that the patient’s data have to be
manually inserted, and dosage adjustments are not automatically in
patient’s medical record, they will be stored in the local databases.
However, according to [10] none of these programs, including Best-
Dose and TCIWorks yet fullls all of the requirements to clinical
pharmokinetics computer program.
During last years (since the review of Fuchs et al. from 2013 [10])
few TDM software tools have been developed. TDMx is a novel
web-based open-access support tool for optimising antimicrobial
dosing regimens in clinical routine [24].TDMx is not a registered
or certied medical device. As result of a research project, TDMx is
provided for personal use only, the accuracy of the provided results
can not be guaranteed9. Currently, TDMx is available for only 4
drugs (meropenem, piperacillin, amikacin and gentamicin).
NextDose is an online dose calculator that uses Bayesian non-
parametric approach to propose dose regimens after concentration
measurements become available. The software consists of three ab-
straction layers and provide a clear separation between the user in-
terface, model controllers and the modeling software. Doseme10 and
insightrx11 are recently available commercial software for TDM.
However, unlike DoseMe and NextDose, TUCUXI allows to cal-
culate population, a priory and a posteriori percentiles. Moreover,
the authors in [1] claim that presently available software (such as
DoseMe, insightrx and NextDose) is still suciently complex and
requires training to enable rapid use at the bedside by healthcare
professionals. In contrast, TUCUXI– TDM software presented in
this paper – has a very intuitive user interface, that makes the soft-
ware easy to use by non-pharmacologists. It can be integrated in
clinical practice, and can also be connected to the research database.
8 CONCLUSIONS
Therapeutic drug monitoring allows to individualize the dose and
helps to ensure the best possible outcome for each patient [13].
7http://www.lapk.org/bestdose.php
8at the time of preparing the review, year 2013
9http://www.tdmx.eu/
10https://doseme.com.au/science-behind-doseme
11www.insight-rx.com
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However, there is still a number of challenges that have to be over-
come before individualized drug dosing based on TDM is widely
used [1]. Software tools developed to automate the process of TDM
are evolving. However, a solution with comprehensive clinical and
research capabilities, showing simplicity, exibility and user friend-
liness is still in demand [10].
In order to address this need and improve dosage adjustment
procedures, TUCUXI , an intelligent automated system, spanning
from the patient’s bedside to research databases has been developed.
This interactive tool is designed to guide a user through the process
of TDM and, therefore, can be used not only by clinical pharmacol-
ogists but also by general practitioners and possibly by educated
patients. We presented the functionalities of the system, user in-
terface, as well as interfaces and messages developed to achieve
interoperability with clinical DMBS and successful integration in
clinical practice.
Correctness of mathematical models embedded in the software,
as well of reliability of data exchange have already been veried.
Currently real world trials to certify the software as medical device
are being developed. Clinical validation by practitioners will fol-
low. Moreover, TUCUXI software can be used to combine patient
care and clinical research by exporting the data for developing new
PKPD models. We also envisage the usage of a mobile TDM soft-
ware embedded in a point-of-care “lab-on-chip“ system, that will
further advance the outcome of drug therapies. In this work, we
also addressed a number of challenges and discussed ethical issues
related to automation of therapeutic drug monitoring in patient
care and medical research.
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